The ALK-1/Smad1 pathway in cardiovascular physiopathology. A new target for therapy?

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 10, 2013, Pages 1492-1510

  González Núñez, María ^a,b,c   Muñoz Félix, José M ^a,b,c   López Novoa, José M ^a,b,c  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA IBSAL   (Spain)

^c Institute Queen Sophie for Renal Research   (Spain)

Author keywords

Angiogenesis; Arteriovenous malformation; HHT; Pulmonary hypertension; Smads; TGF

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; BONE MORPHOGENETIC PROTEIN 9; ENDOGLIN; IMATINIB; LDN 193189; PFO 3446962; PROTEIN INHIBITOR; RAP 041; SMAD1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIOVENOUS MALFORMATION; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CELL MIGRATION; CELL PROLIFERATION; CELL TYPE; CLINICAL TRIAL; DRUG TARGETING; FIBROBLAST; GENE MUTATION; HAPLOINSUFFICIENCY; HOMEOSTASIS; HUMAN; MACROPHAGE; MONOCYTE; MYOBLAST; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RENDU OSLER WEBER DISEASE; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TISSUE REGENERATION;

ANGIOGENESIS; ARTERIOVENOUS MALFORMATION; HHT; PULMONARY HYPERTENSION; SMADS; TGF-Β;

ACTIVIN RECEPTORS, TYPE II; CARDIOVASCULAR DISEASES; HOMEOSTASIS; HUMANS; SIGNAL TRANSDUCTION; SMAD1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA; MUS;

EID: 84879382659     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.05.016     Document Type: Review

References (249)

1. Massague J. How cells read TGF-beta signals. Nat. Rev. Mol. Cell Biol. 2000, 1:169-178.
2. Goumans M.J., Valdimarsdottir G., Itoh S., Rosendahl A., Sideras P., ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J. 2002, 21:1743-1753.
3. Lebrin F., Deckers M., Bertolino P., Ten Dijke P. TGF-beta receptor function in the endothelium. Cardiovasc. Res. 2005, 65:599-608.
4. Velasco S., Alvarez-Munoz P., Pericacho M., Dijke P.T., Bernabeu C., Lopez-Novoa J.M., Rodriguez-Barbero A. L- and S-endoglin differentially modulate TGFbeta1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts. J. Cell Sci. 2008, 121:913-919.
5. Cunha S.I., Pardali E., Thorikay M., Anderberg C., Hawinkels L., Goumans M.J., Seehra J., Heldin C.H., ten Dijke P., Pietras K. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J. Exp. Med. 2010, 207:85-100.
6. Goumans M.J., Liu Z., ten Dijke P. TGF-beta signaling in vascular biology and dysfunction. Cell Res. 2009, 19:116-127.
7. Lopez-Novoa J.M., Bernabeu C. The physiological role of endoglin in the cardiovascular system. Am. J. Physiol. Heart Circ. Physiol. 2010, 299:H959-H974.
8. Grainger D.J. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler. Thromb. Vasc. Biol. 2004, 24:399-404.
9. Grainger D.J. TGF-beta and atherosclerosis in man. Cardiovasc. Res. 2007, 74:213-222.
10. Gordon K.J., Dong M., Chislock E.M., Fields T.A., Blobe G.C. Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. Carcinogenesis 2008, 29:252-262.
11. Lavoie P., Robitaille G., Agharazii M., Ledbetter S., Lebel M., Lariviere R. Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. J. Hypertens. 2005, 23:1895-1903.
12. Gordon K.J., Blobe G.C. Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim. Biophys. Acta 2008, 1782:197-228.
13. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc. Res. 2004, 63:423-432.
14. Machado R.D., Pauciulo M.W., Thomson J.R., Lane K.B., Morgan N.V., Wheeler L., Phillips J.A., Newman J., Williams D., Galie N., Manes A., McNeil K., Yacoub M., Mikhail G., Rogers P., Corris P., Humbert M., Donnai D., Martensson G., Tranebjaerg L., Loyd J.E., Trembath R.C., Nichols W.C. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am. J. Hum. Genet. 2001, 68:92-102.
15. Harrison R.E., Berger R., Haworth S.G., Tulloh R., Mache C.J., Morrell N.W., Aldred M.A., Trembath R.C. Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. Circulation 2005, 111:435-441.
16. Jerkic M., Kabir M.G., Davies A., Yu L.X., McIntyre B.A., Husain N.W., Enomoto M., Sotov V., Husain M., Henkelman M., Belik J., Letarte M. Pulmonary hypertension in adult Alk1 heterozygous mice due to oxidative stress. Cardiovasc. Res. 2011, 92:375-384.
17. Rifkin D.B. Latent transforming growth factor-beta (TGF-beta) binding proteins: orchestrators of TGF-beta availability. J. Biol. Chem. 2005, 280:7409-7412.
18. Miyazono K., Kamiya Y., Morikawa M. Bone morphogenetic protein receptors and signal transduction. J. Biochem. 2010, 147:35-51.
19. Rider C.C., Mulloy B. Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists. Biochem. J. 2010, 429:1-12.
20. Chen G., Deng C., Li Y.P. TGF-beta and BMP signaling in osteoblast differentiation and bone formation. Int. J. Biol. Sci. 2012, 8:272-288.
21. Massague J. A very private TGF-beta receptor embrace. Mol. Cell 2008, 29:149-150.
22. Samad T.A., Rebbapragada A., Bell E., Zhang Y., Sidis Y., Jeong S.J., Campagna J.A., Perusini S., Fabrizio D.A., Schneyer A.L., Lin H.Y., Brivanlou A.H., Attisano L., Woolf C.J. DRAGON, a bone morphogenetic protein co-receptor. J. Biol. Chem. 2005, 280:14122-14129.
23. Canalis E., Economides A.N., Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr. Rev. 2003, 24:218-235.
24. Mezzano S., Droguett A., Burgos M.E., Aros C., Ardiles L., Flores C., Carpio D., Carvajal G., Ruiz-Ortega M., Egido J. Expression of gremlin, a bone morphogenetic protein antagonist, in glomerular crescents of pauci-immune glomerulonephritis. Nephrol. Dial. Transplant. 2007, 22:1882-1890.
25. Zebboudj A.F., Imura M., Bostrom K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J. Biol. Chem. 2002, 277:4388-4394.
26. Zhou Z., Xie J., Lee D., Liu Y., Jung J., Zhou L., Xiong S., Mei L., Xiong W.C. Neogenin regulation of BMP-induced canonical Smad signaling and endochondral bone formation. Dev. Cell 2010, 19:90-102.
27. Brown M.A., Zhao Q., Baker K.A., Naik C., Chen C., Pukac L., Singh M., Tsareva T., Parice Y., Mahoney A., Roschke V., Sanyal I., Choe S. Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J. Biol. Chem. 2005, 280:25111-25118.
28. Lopez-Coviella I., Berse B., Krauss R., Thies R.S., Blusztajn J.K. Induction and maintenance of the neuronal cholinergic phenotype in the central nervous system by BMP-9. Science 2000, 289:313-316.
29. Kang Q., Sun M.H., Cheng H., Peng Y., Montag A.G., Deyrup A.T., Jiang W., Luu H.H., Luo J., Szatkowski J.P., Vanichakarn P., Park J.Y., Li Y., Haydon R.C., He T.C. Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther. 2004, 11:1312-1320.
30. Majumdar M.K., Wang E., Morris E.A. BMP-2 and BMP-9 promotes chondrogenic differentiation of human multipotential mesenchymal cells and overcomes the inhibitory effect of IL-1. J. Cell. Physiol. 2001, 189:275-284.
31. Chen C., Grzegorzewski K.J., Barash S., Zhao Q., Schneider H., Wang Q., Singh M., Pukac L., Bell A.C., Duan R., Coleman T., Duttaroy A., Cheng S., Hirsch J., Zhang L., Lazard Y., Fischer C., Barber M.C., Ma Z.D., Zhang Y.Q., Reavey P., Zhong L., Teng B., Sanyal I., Ruben S.M., Blondel O., Birse C.E. An integrated functional genomics screening program reveals a role for BMP-9 in glucose homeostasis. Nat. Biotechnol. 2003, 21:294-301.
32. Truksa J., Peng H., Lee P., Beutler E. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:10289-10293.
33. Miller A.F., Harvey S.A., Thies R.S., Olson M.S. Bone morphogenetic protein-9. An autocrine/paracrine cytokine in the liver. J. Biol. Chem. 2000, 275:17937-17945.
34. David L., Mallet C., Mazerbourg S., Feige J.J., Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 2007, 109:1953-1961.
35. Scharpfenecker M., van Dinther M., Liu Z., van Bezooijen R.L., Zhao Q., Pukac L., Lowik C.W., ten Dijke P. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J. Cell Sci. 2007, 120:964-972.
36. Lin S.J., Lerch T.F., Cook R.W., Jardetzky T.S., Woodruff T.K. The structural basis of TGF-beta, bone morphogenetic protein, and activin ligand binding. Reproduction 2006, 132:179-190.
37. Chen D., Zhao M., Mundy G.R. Bone morphogenetic proteins. Growth Factors 2004, 22:233-241.
38. Ricard N., Ciais D., Levet S., Subileau M., Mallet C., Zimmers T.A., Lee S.J., Bidart M., Feige J.J., Bailly S. BMP9 and BMP10 are critical for postnatal retinal vascular remodeling. Blood 2012, 119:6162-6171.
39. Massague J., Cheifetz S., Boyd F.T., Andres J.L. TGF-beta receptors and TGF-beta binding proteoglycans: recent progress in identifying their functional properties. Ann. N. Y. Acad. Sci. 1990, 593:59-72.
40. Burt D.W., Paton I.R. Evolutionary origins of the transforming growth factor-beta gene family. DNA Cell Biol. 1992, 11:497-510.
41. Vempati U.D., Kondaiah P. Molecular organization of the gene encoding Xenopus laevis transforming growth factor-beta 5. Biochem. Mol. Biol. Int. 1998, 45:997-1003.
42. Prieto M., Rivas J.V., Lopez Novoa J.M., Perez-Barriocanal F. TGF-beta: synthesis and mechanism of action. Nefrologia 2002, 22:135-143.
43. Lopez-Hernandez F.J., Lopez-Novoa J.M. Role of TGF-beta in chronic kidney disease: an integration of tubular, glomerular and vascular effects. Cell Tissue Res. 2012, 347:141-154.
44. Dooley S., ten Dijke P. TGF-beta in progression of liver disease. Cell Tissue Res. 2012, 347:245-256.
45. Morris E., Chrobak I., Bujor A., Hant F., Mummery C., Ten Dijke P., Trojanowska M. Endoglin promotes TGF-beta/Smad1 signaling in scleroderma fibroblasts. J. Cell. Physiol. 2011, 226:3340-3348.
46. Kapur N.K., Wilson S., Yunis A.A., Qiao X., Mackey E., Paruchuri V., Baker C., Aronovitz M.J., Karumanchi S.A., Letarte M., Kass D.A., Mendelsohn M.E., Karas R.H. Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure. Circulation 2012, 125:2728-2738.
47. Bertolino P., Deckers M., Lebrin F., ten Dijke P. Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders. Chest 2005, 128:585S-590S.
48. Lamouille S., Mallet C., Feige J.J., Bailly S. Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis. Blood 2002, 100:4495-4501.
49. Hinck A.P. Structural studies of the TGF-betas and their receptors-insights into evolution of the TGF-beta superfamily. FEBS Lett. 2012, 586:1860-1870.
50. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
51. Miyazawa K., Shinozaki M., Hara T., Furuya T., Miyazono K. Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells 2002, 7:1191-1204.
52. Ikushima H., Komuro A., Isogaya K., Shinozaki M., Hellman U., Miyazawa K., Miyazono K. An Id-like molecule, HHM, is a synexpression group-restricted regulator of TGF-beta signalling. EMBO J. 2008, 27:2955-2965.
53. Wrighton K.H., Feng X.H. To (TGF)beta or not to (TGF)beta: fine-tuning of Smad signaling via post-translational modifications. Cell. Signal. 2008, 20:1579-1591.
54. Liu I.M., Schilling S.H., Knouse K.A., Choy L., Derynck R., Wang X.F. TGFbeta-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFbeta switch. EMBO J. 2009, 28:88-98.
55. Itoh S., ten Dijke P. Negative regulation of TGF-beta receptor/Smad signal transduction. Curr. Opin. Cell Biol. 2007, 19:176-184.
56. Bennett D., Alphey L. PP1 binds Sara and negatively regulates Dpp signaling in Drosophila melanogaster. Nat. Genet. 2002, 31:419-423.
57. Valdimarsdottir G., Goumans M.J., Itoh F., Itoh S., Heldin C.H., ten Dijke P. Smad7 and protein phosphatase 1alpha are critical determinants in the duration of TGF-beta/ALK1 signaling in endothelial cells. BMC Cell Biol. 2006, 7:16.
58. Krakowski A.R., Laboureau J., Mauviel A., Bissell M.J., Luo K. Cytoplasmic SnoN in normal tissues and nonmalignant cells antagonizes TGF-beta signaling by sequestration of the Smad proteins. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:12437-12442.
59. Lin F., Morrison J.M., Wu W., Worman H.J. MAN1, an integral protein of the inner nuclear membrane, binds Smad2 and Smad3 and antagonizes transforming growth factor-beta signaling. Hum. Mol. Genet. 2005, 14:437-445.
60. Pan D., Estevez-Salmeron L.D., Stroschein S.L., Zhu X., He J., Zhou S., Luo K. The integral inner nuclear membrane protein MAN1 physically interacts with the R-Smad proteins to repress signaling by the transforming growth factor-{beta} superfamily of cytokines. J. Biol. Chem. 2005, 280:15992-16001.
61. Remy I., Montmarquette A., Michnick S.W. PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. Nat. Cell Biol. 2004, 6:358-365.
62. Conery A.R., Cao Y., Thompson E.A., Townsend C.M., Ko T.C., Luo K. Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis. Nat. Cell Biol. 2004, 6:366-372.
63. He W., Dorn D.C., Erdjument-Bromage H., Tempst P., Moore M.A., Massague J. Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell 2006, 125:929-941.
64. Moustakas A., Heldin C.H. Non-Smad TGF-beta signals. J. Cell Sci. 2005, 118:3573-3584.
65. Zhang Y.E. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009, 19:128-139.
66. Galliher A.J., Schiemann W.P. Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res. 2007, 67:3752-3758.
67. Lee M.K., Pardoux C., Hall M.C., Lee P.S., Warburton D., Qing J., Smith S.M., Derynck R. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J. 2007, 26:3957-3967.
68. Zavadil J., Bitzer M., Liang D., Yang Y.C., Massimi A., Kneitz S., Piek E., Bottinger E.P. Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:6686-6691.
69. Davies M., Robinson M., Smith E., Huntley S., Prime S., Paterson I. Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways. J. Cell. Biochem. 2005, 95:918-931.
70. Rodriguez-Barbero A., Obreo J., Alvarez-Munoz P., Pandiella A., Bernabeu C., Lopez-Novoa J.M. Endoglin modulation of TGF-beta1-induced collagen synthesis is dependent on ERK1/2 MAPK activation. Cell. Physiol. Biochem. 2006, 18:135-142.
71. Pannu J., Nakerakanti S., Smith E., ten Dijke P., Trojanowska M. Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J. Biol. Chem. 2007, 282:10405-10413.
72. Funaba M., Zimmerman C.M., Mathews L.S. Modulation of Smad2-mediated signaling by extracellular signal-regulated kinase. J. Biol. Chem. 2002, 277:41361-41368.
73. Matsuura I., Wang G., He D., Liu F. Identification and characterization of ERK MAP kinase phosphorylation sites in Smad3. Biochemistry 2005, 44:12546-12553.
74. Kretzschmar M., Doody J., Timokhina I., Massague J. A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes Dev. 1999, 13:804-816.
75. Frey R.S., Mulder K.M. Involvement of extracellular signal-regulated kinase 2 and stress-activated protein kinase/Jun N-terminal kinase activation by transforming growth factor beta in the negative growth control of breast cancer cells. Cancer Res. 1997, 57:628-633.
76. Hocevar B.A., Brown T.L., Howe P.H. TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J. 1999, 18:1345-1356.
77. Hanafusa H., Ninomiya-Tsuji J., Masuyama N., Nishita M., Fujisawa J., Shibuya H., Matsumoto K., Nishida E. Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-beta-induced gene expression. J. Biol. Chem. 1999, 274:27161-27167.
78. Bhowmick N.A., Ghiassi M., Bakin A., Aakre M., Lundquist C.A., Engel M.E., Arteaga C.L., Moses H.L. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol. Biol. Cell 2001, 12:27-36.
79. Yu L., Hebert M.C., Zhang Y.E. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J. 2002, 21:3749-3759.
80. Kimura N., Matsuo R., Shibuya H., Nakashima K., Taga T. BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6. J. Biol. Chem. 2000, 275:17647-17652.
81. Edlund S., Bu S., Schuster N., Aspenstrom P., Heuchel R., Heldin N.E., ten Dijke P., Heldin C.H., Landstrom M. Transforming growth factor-beta1 (TGF-beta)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-beta-activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol. Biol. Cell 2003, 14:529-544.
82. Yamashita M., Fatyol K., Jin C., Wang X., Liu Z., Zhang Y.E. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol. Cell 2008, 31:918-924.
83. Jaffe A.B., Hall A. Rho GTPases: biochemistry and biology. Annu. Rev. Cell Dev. Biol. 2005, 21:247-269.
84. Bhowmick N.A., Zent R., Ghiassi M., McDonnell M., Moses H.L. Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity. J. Biol. Chem. 2001, 276:46707-46713.
85. Lamouille S., Derynck R. Emergence of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin axis in transforming growth factor-beta-induced epithelial-mesenchymal transition. Cells Tissues Organs 2011, 193:8-22.
86. Grande M.T., Arevalo M., Nunez A., Cannata-Andia J.B., Santos E., Lopez-Novoa J.M. Targeted genomic disruption of H-ras and N-ras has no effect on early renal changes after unilateral ureteral ligation. World J. Urol. 2009, 27:787-797.
87. Yi J.Y., Shin I., Arteaga C.L. Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase. J. Biol. Chem. 2005, 280:10870-10876.
88. Lamouille S., Derynck R. Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J. Cell Biol. 2007, 178:437-451.
89. ten Dijke P., Franzen P., Yamashita H., Ichijo H., Heldin C.H., Miyazono K. Serine/threonine kinase receptors. Prog. Growth Factor Res. 1994, 5:55-72.
90. Groppe J., Hinck C.S., Samavarchi-Tehrani P., Zubieta C., Schuermann J.P., Taylor A.B., Schwarz P.M., Wrana J.L., Hinck A.P. Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol. Cell 2008, 29:157-168.
91. David L., Feige J.J., Bailly S. Emerging role of bone morphogenetic proteins in angiogenesis. Cytokine Growth Factor Rev. 2009, 20:203-212.
92. Garrido-Martin E.M., Blanco F.J., Fernandez L.A., Langa C., Vary C.P., Lee U.E., Friedman S.L., Botella L.M., Bernabeu C. Characterization of the human Activin-A receptor type II-like kinase 1 (ACVRL1) promoter and its regulation by Sp1. BMC Mol. Biol. 2010, 11:51.
93. ten Dijke P., Ichijo H., Franzen P., Schulz P., Saras J., Toyoshima H., Heldin C.H., Miyazono K. Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity. Oncogene 1993, 8:2879-2887.
94. Attisano L., Carcamo J., Ventura F., Weis F.M., Massague J., Wrana J.L. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell 1993, 75:671-680.
95. Wu X., Robinson C.E., Fong H.W., Crabtree J.S., Rodriguez B.R., Roe B.A., Gimble J.M. Cloning and characterization of the murine activin receptor like kinase-1 (ALK-1) homolog. Biochem. Biophys. Res. Commun. 1995, 216:78-83.
96. Panchenko M.P., Williams M.C., Brody J.S., Yu Q. Type I receptor serine-threonine kinase preferentially expressed in pulmonary blood vessels. Am. J. Physiol. 1996, 270:L547-L558.
97. Roelen B.A., van Rooijen M.A., Mummery C.L. Expression of ALK-1, a type 1 serine/threonine kinase receptor, coincides with sites of vasculogenesis and angiogenesis in early mouse development. Dev. Dyn. 1997, 209:418-430.
98. He W.W., Gustafson M.L., Hirobe S., Donahoe P.K. Developmental expression of four novel serine/threonine kinase receptors homologous to the activin/transforming growth factor-beta type II receptor family. Dev. Dyn. 1993, 196:133-142.
99. Mahmoud M., Borthwick G.M., Hislop A.A., Arthur H.M. Endoglin and activin receptor-like-kinase 1 are co-expressed in the distal vessels of the lung: implications for two familial vascular dysplasias, HHT and PAH. Lab. Invest. 2009, 89:15-25.
100. Seki T., Yun J., Oh S.P. Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling. Circ. Res. 2003, 93:682-689.
101. Torsney E., Charlton R., Parums D., Collis M., Arthur H.M. Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm. Res. 2002, 51:464-470.
102. van Laake L.W., van den Driesche S., Post S., Feijen A., Jansen M.A., Driessens M.H., Mager J.J., Snijder R.J., Westermann C.J., Doevendans P.A., van Echteld C.J., ten Dijke P., Arthur H.M., Goumans M.J., Lebrin F., Mummery C.L. Endoglin has a crucial role in blood cell-mediated vascular repair. Circulation 2006, 114:2288-2297.
103. Wiercinska E., Wickert L., Denecke B., Said H.M., Hamzavi J., Gressner A.M., Thorikay M., ten Dijke P., Mertens P.R., Breitkopf K., Dooley S. Id1 is a critical mediator in TGF-beta-induced transdifferentiation of rat hepatic stellate cells. Hepatology 2006, 43:1032-1041.
104. Finnson K.W., Parker W.L., ten Dijke P., Thorikay M., Philip A. ALK1 opposes ALK5/Smad3 signaling and expression of extracellular matrix components in human chondrocytes. J. Bone Miner. Res. 2008, 23:896-906.
105. Su A.I., Wiltshire T., Batalov S., Lapp H., Ching K.A., Block D., Zhang J., Soden R., Hayakawa M., Kreiman G., Cooke M.P., Walker J.R., Hogenesch J.B. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:6062-6067.
106. Sanz-Rodriguez F., Fernandez L.A., Zarrabeitia R., Perez-Molino A., Ramirez J.R., Coto E., Bernabeu C., Botella L.M. Mutation analysis in Spanish patients with hereditary hemorrhagic telangiectasia: deficient endoglin up-regulation in activated monocytes. Clin. Chem. 2004, 50:2003-2011.
107. Mancini M.L., Verdi J.M., Conley B.A., Nicola T., Spicer D.B., Oxburgh L.H., Vary C.P. Endoglin is required for myogenic differentiation potential of neural crest stem cells. Dev. Biol. 2007, 308:520-533.
108. Beger B., Robertson K., Evans A., Grant A., Berg J. Expression of endoglin and the activin receptor-like kinase 1 in skin suggests a role for these receptors in normal skin function and skin tumorigenesis. Br. J. Dermatol. 2006, 154:379-382.
109. Konig H.G., Kogel D., Rami A., Prehn J.H. TGF-{beta}1 activates two distinct type I receptors in neurons: implications for neuronal NF-{kappa}B signaling. J. Cell Biol. 2005, 168:1077-1086.
110. Sorensen L.K., Brooke B.S., Li D.Y., Urness L.D. Loss of distinct arterial and venous boundaries in mice lacking endoglin, a vascular-specific TGFbeta coreceptor. Dev. Biol. 2003, 261:235-250.
111. Urness L.D., Sorensen L.K., Li D.Y. Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat. Genet. 2000, 26:328-331.
112. Seki T., Hong K.H., Oh S.P. Nonoverlapping expression patterns of ALK1 and ALK5 reveal distinct roles of each receptor in vascular development. Lab. Invest. 2006, 86:116-129.
113. Goumans M.J., Valdimarsdottir G., Itoh S., Lebrin F., Larsson J., Mummery C., Karlsson S., ten Dijke P. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol. Cell 2003, 12:817-828.
114. ten Dijke P., Yamashita H., Ichijo H., Franzen P., Laiho M., Miyazono K., Heldin C.H. Characterization of type I receptors for transforming growth factor-beta and activin. Science 1994, 264:101-104.
115. Oh S.P., Seki T., Goss K.A., Imamura T., Yi Y., Donahoe P.K., Li L., Miyazono K., ten Dijke P., Kim S., Li E. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:2626-2631.
116. Lux A., Attisano L., Marchuk D.A. Assignment of transforming growth factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1. J. Biol. Chem. 1999, 274:9984-9992.
117. Lebrin F., Goumans M.J., Jonker L., Carvalho R.L., Valdimarsdottir G., Thorikay M., Mummery C., Arthur H.M., ten Dijke P. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J. 2004, 23:4018-4028.
118. Macias-Silva M., Hoodless P.A., Tang S.J., Buchwald M., Wrana J.L. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2. J. Biol. Chem. 1998, 273:25628-25636.
119. Goumans M.J., Lebrin F., Valdimarsdottir G. Controlling the angiogenic switch: a balance between two distinct TGF-b receptor signaling pathways. Trends Cardiovasc. Med. 2003, 13:301-307.
120. Mo J., Fang S.J., Chen W., Blobe G.C. Regulation of ALK-1 signaling by the nuclear receptor LXRbeta. J. Biol. Chem. 2002, 277:50788-50794.
121. Blanco F.J., Santibanez J.F., Guerrero-Esteo M., Langa C., Vary C.P., Bernabeu C. Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J. Cell. Physiol. 2005, 204:574-584.
122. Townson S.A., Martinez-Hackert E., Greppi C., Lowden P., Sako D., Liu J., Ucran J.A., Liharska K., Underwood K.W., Seehra J., Kumar R., Grinberg A.V. Specificity and structure of a high affinity activin receptor-like kinase 1 (ALK1) signaling complex. J. Biol. Chem. 2012, 287:27313-27325.
123. Lee N.Y., Haney J.C., Sogani J., Blobe G.C. Casein kinase 2beta as a novel enhancer of activin-like receptor-1 signaling. FASEB J. 2009, 23:3712-3721.
124. Upton P.D., Davies R.J., Trembath R.C., Morrell N.W. Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells. J. Biol. Chem. 2009, 284:15794-15804.
125. Wrana J.L., Attisano L., Wieser R., Ventura F., Massague J. Mechanism of activation of the TGF-beta receptor. Nature 1994, 370:341-347.
126. Wang T., Li B.Y., Danielson P.D., Shah P.C., Rockwell S., Lechleider R.J., Martin J., Manganaro T., Donahoe P.K. The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors. Cell 1996, 86:435-444.
127. Chen Y.G., Liu F., Massague J. Mechanism of TGFbeta receptor inhibition by FKBP12. EMBO J. 1997, 16:3866-3876.
128. Pece-Barbara N., Vera S., Kathirkamathamby K., Liebner S., Di Guglielmo G.M., Dejana E., Wrana J.L., Letarte M. Endoglin null endothelial cells proliferate faster and are more responsive to transforming growth factor beta1 with higher affinity receptors and an activated Alk1 pathway. J. Biol. Chem. 2005, 280:27800-27808.
129. Santibanez J.F., Blanco F.J., Garrido-Martin E.M., Sanz-Rodriguez F., del Pozo M.A., Bernabeu C. Caveolin-1 interacts and cooperates with the transforming growth factor-beta type I receptor ALK1 in endothelial caveolae. Cardiovasc. Res. 2008, 77:791-799.
130. Gougos A., St Jacques S., Greaves A., O'Connell P.J., d'Apice A.J., Buhring H.J., Bernabeu C., van Mourik J.A., Letarte M. Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int. Immunol. 1992, 4:83-92.
131. Jovine L., Darie C.C., Litscher E.S., Wassarman P.M. Zona pellucida domain proteins. Annu. Rev. Biochem. 2005, 74:83-114.
132. Llorca O., Trujillo A., Blanco F.J., Bernabeu C. Structural model of human endoglin, a transmembrane receptor responsible for hereditary hemorrhagic telangiectasia. J. Mol. Biol. 2007, 365:694-705.
133. Gougos A., Letarte M. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J. Biol. Chem. 1990, 265:8361-8364.
134. Bellon T., Corbi A., Lastres P., Cales C., Cebrian M., Vera S., Cheifetz S., Massague J., Letarte M., Bernabeu C. Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur. J. Immunol. 1993, 23:2340-2345.
135. Perez-Gomez E., Eleno N., Lopez-Novoa J.M., Ramirez J.R., Velasco B., Letarte M., Bernabeu C., Quintanilla M. Characterization of murine S-endoglin isoform and its effects on tumor development. Oncogene 2005, 24:4450-4461.
136. Bernabeu C., Lopez-Novoa J.M., Quintanilla M. The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim. Biophys. Acta 2009, 1792:954-973.
137. Venkatesha S., Toporsian M., Lam C., Hanai J., Mammoto T., Kim Y.M., Bdolah Y., Lim K.H., Yuan H.T., Libermann T.A., Stillman I.E., Roberts D., D'Amore P.A., Epstein F.H., Sellke F.W., Romero R., Sukhatme V.P., Letarte M., Karumanchi S.A. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 2006, 12:642-649.
138. Cheifetz S., Bellon T., Cales C., Vera S., Bernabeu C., Massague J., Letarte M. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J. Biol. Chem. 1992, 267:19027-19030.
139. Guerrero-Esteo M., Sanchez-Elsner T., Letamendia A., Bernabeu C. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J. Biol. Chem. 2002, 277:29197-29209.
140. Jonker L., Arthur H.M. Endoglin expression in early development is associated with vasculogenesis and angiogenesis. Mech. Dev. 2002, 110:193-196.
141. Perlingeiro R.C. Endoglin is required for hemangioblast and early hematopoietic development. Development 2007, 134:3041-3048.
142. Szekanecz Z., Haines G.K., Harlow L.A., Shah M.R., Fong T.W., Fu R., Lin S.J., Rayan G., Koch A.E. Increased synovial expression of transforming growth factor (TGF)-beta receptor endoglin and TGF-beta 1 in rheumatoid arthritis: possible interactions in the pathogenesis of the disease. Clin. Immunol. Immunopathol. 1995, 76:187-194.
143. Botella L.M., Sanchez-Elsner T., Sanz-Rodriguez F., Kojima S., Shimada J., Guerrero-Esteo M., Cooreman M.P., Ratziu V., Langa C., Vary C.P., Ramirez J.R., Friedman S., Bernabeu C. Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood 2002, 100:4001-4010.
144. Burrows F.J., Derbyshire E.J., Tazzari P.L., Amlot P., Gazdar A.F., King S.W., Letarte M., Vitetta E.S., Thorpe P.E. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin. Cancer Res. 1995, 1:1623-1634.
145. Miller D.W., Graulich W., Karges B., Stahl S., Ernst M., Ramaswamy A., Sedlacek H.H., Muller R., Adamkiewicz J. Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells. Int. J. Cancer 1999, 81:568-572.
146. Fonsatti E., Jekunen A.P., Kairemo K.J., Coral S., Snellman M., Nicotra M.R., Natali P.G., Altomonte M., Maio M. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin. Cancer Res. 2000, 6:2037-2043.
147. Docherty N.G., Lopez-Novoa J.M., Arevalo M., Duwel A., Rodriguez-Pena A., Perez-Barriocanal F., Bernabeu C., Eleno N. Endoglin regulates renal ischaemia-reperfusion injury. Nephrol. Dial. Transplant. 2006, 21:2106-2119.
148. Jerkic M., Rodriguez-Barbero A., Prieto M., Toporsian M., Pericacho M., Rivas-Elena J.V., Obreo J., Wang A., Perez-Barriocanal F., Arevalo M., Bernabeu C., Letarte M., Lopez-Novoa J.M. Reduced angiogenic responses in adult Endoglin heterozygous mice. Cardiovasc. Res. 2006, 69:845-854.
149. Lastres P., Bellon T., Cabanas C., Sanchez-Madrid F., Acevedo A., Gougos A., Letarte M., Bernabeu C. Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur. J. Immunol. 1992, 22:393-397.
150. Rodriguez-Pena A., Eleno N., Duwell A., Arevalo M., Perez-Barriocanal F., Flores O., Docherty N., Bernabeu C., Letarte M., Lopez-Novoa J.M. Endoglin upregulation during experimental renal interstitial fibrosis in mice. Hypertension 2002, 40:713-720.
151. Clemente M., Nunez O., Lorente R., Rincon D., Matilla A., Salcedo M., Catalina M.V., Ripoll C., Iacono O.L., Banares R., Clemente G., Garcia-Monzon C. Increased intrahepatic and circulating levels of endoglin, a TGF-beta1 co-receptor, in patients with chronic hepatitis C virus infection: relationship to histological and serum markers of hepatic fibrosis. J. Viral Hepat. 2006, 13:625-632.
152. Conley B.A., Smith J.D., Guerrero-Esteo M., Bernabeu C., Vary C.P. Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis 2000, 153:323-335.
153. Nachtigal P., Zemankova Vecerova L., Rathouska J., Strasky Z. The role of endoglin in atherosclerosis. Atherosclerosis 2012, 224:4-11.
154. Diez-Marques L., Ortega-Velazquez R., Langa C., Rodriguez-Barbero A., Lopez-Novoa J.M., Lamas S., Bernabeu C. Expression of endoglin in human mesangial cells: modulation of extracellular matrix synthesis. Biochim. Biophys. Acta 2002, 1587:36-44.
155. McAllister K.A., Grogg K.M., Johnson D.W., Gallione C.J., Baldwin M.A., Jackson C.E., Helmbold E.A., Markel D.S., McKinnon W.C., Murrell J., et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat. Genet. 1994, 8:345-351.
156. Govani F.S., Shovlin C.L. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur. J. Hum. Genet. 2009, 17:860-871.
157. Blanco F.J., Grande M.T., Langa C., Oujo B., Velasco S., Rodriguez-Barbero A., Perez-Gomez E., Quintanilla M., Lopez-Novoa J.M., Bernabeu C. S-endoglin expression is induced in senescent endothelial cells and contributes to vascular pathology. Circ. Res. 2008, 103:1383-1392.
158. Li C., Guo B., Wilson P.B., Stewart A., Byrne G., Bundred N., Kumar S. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int. J. Cancer 2000, 89:122-126.
159. Calabro L., Fonsatti E., Bellomo G., Alonci A., Colizzi F., Sigalotti L., Altomonte M., Musolino C., Maio M. Differential levels of soluble endoglin (CD105) in myeloid malignancies. J. Cell. Physiol. 2003, 194:171-175.
160. Lopez-Novoa J.M. Soluble endoglin is an accurate predictor and a pathogenic molecule in pre-eclampsia. Nephrol. Dial. Transplant. 2007, 22:712-714.
161. Kaitu'u-Lino T.J., Palmer K.R., Whitehead C.L., Williams E., Lappas M., Tong S. MMP-14 is expressed in preeclamptic placentas and mediates release of soluble endoglin. Am. J. Pathol. 2012, 180:888-894.
162. Valbuena-Diez A.C., Blanco F.J., Oujo B., Langa C., Gonzalez-Nunez M., Llano E., Pendas A.M., Diaz M., Castrillo A., Lopez-Novoa J.M., Bernabeu C. Oxysterol-induced soluble endoglin release and its involvement in hypertension. Circulation 2012, 126:2612-2624.
163. Chen Y., Hao Q., Kim H., Su H., Letarte M., Karumanchi S.A., Lawton M.T., Barbaro N.M., Yang G.Y., Young W.L. Soluble endoglin modulates aberrant cerebral vascular remodeling. Ann. Neurol. 2009, 66:19-27.
164. Jerkic M., Rivas-Elena J.V., Prieto M., Carron R., Sanz-Rodriguez F., Perez-Barriocanal F., Rodriguez-Barbero A., Bernabeu C., Lopez-Novoa J.M. Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J. 2004, 18:609-611.
165. Toporsian M., Gros R., Kabir M.G., Vera S., Govindaraju K., Eidelman D.H., Husain M., Letarte M. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ. Res. 2005, 96:684-692.
166. ten Dijke P., Arthur H.M. Extracellular control of TGFbeta signalling in vascular development and disease. Nat. Rev. Mol. Cell Biol. 2007, 8:857-869.
167. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288:373-376.
168. Flammer A.J., Anderson T., Celermajer D.S., Creager M.A., Deanfield J., Ganz P., Hamburg N.M., Luscher T.F., Shechter M., Taddei S., Vita J.A., Lerman A. The assessment of endothelial function: from research into clinical practice. Circulation 2012, 126:753-767.
169. Ruiz-Ortega M., Rodriguez-Vita J., Sanchez-Lopez E., Carvajal G., Egido J. TGF-beta signaling in vascular fibrosis. Cardiovasc. Res. 2007, 74:196-206.
170. Yao Y., Zebboudj A.F., Torres A., Shao E., Bostrom K. Activin-like kinase receptor 1 (ALK1) in atherosclerotic lesions and vascular mesenchymal cells. Cardiovasc. Res. 2007, 74:279-289.
171. Tang Y., Yang X., Friesel R.E., Vary C.P., Liaw L. Mechanisms of TGF-beta-induced differentiation in human vascular smooth muscle cells. J. Vasc. Res. 2011, 48:485-494.
172. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
173. Mitchell D., Pobre E.G., Mulivor A.W., Grinberg A.V., Castonguay R., Monnell T.E., Solban N., Ucran J.A., Pearsall R.S., Underwood K.W., Seehra J., Kumar R. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol. Cancer Ther. 2010, 9:379-388.
174. Chen H., Shi S., Acosta L., Li W., Lu J., Bao S., Chen Z., Yang Z., Schneider M.D., Chien K.R., Conway S.J., Yoder M.C., Haneline L.S., Franco D., Shou W. BMP10 is essential for maintaining cardiac growth during murine cardiogenesis. Development 2004, 131:2219-2231.
175. Johnson D.W., Berg J.N., Baldwin M.A., Gallione C.J., Marondel I., Yoon S.J., Stenzel T.T., Speer M., Pericak-Vance M.A., Diamond A., Guttmacher A.E., Jackson C.E., Attisano L., Kucherlapati R., Porteous M.E., Marchuk D.A. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat. Genet. 1996, 13:189-195.
176. Shintani M., Yagi H., Nakayama T., Saji T., Matsuoka R. A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension. J. Med. Genet. 2009, 46:331-337.
177. Lane K.B., Machado R.D., Pauciulo M.W., Thomson J.R., Phillips J.A., Loyd J.E., Nichols W.C., Trembath R.C. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat. Genet. 2000, 26:81-84.
178. Gallione C.J., Richards J.A., Letteboer T.G., Rushlow D., Prigoda N.L., Leedom T.P., Ganguly A., Castells A., Ploos van Amstel J.K., Westermann C.J., Pyeritz R.E., Marchuk D.A. SMAD4 mutations found in unselected HHT patients. J. Med. Genet. 2006, 43:793-797.
179. Roman B.L., Pham V.N., Lawson N.D., Kulik M., Childs S., Lekven A.C., Garrity D.M., Moon R.T., Fishman M.C., Lechleider R.J., Weinstein B.M. Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels. Development 2002, 129:3009-3019.
180. David L., Mallet C., Keramidas M., Lamande N., Gasc J.M., Dupuis-Girod S., Plauchu H., Feige J.J., Bailly S. Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ. Res. 2008, 102:914-922.
181. Suzuki Y., Ohga N., Morishita Y., Hida K., Miyazono K., Watabe T. BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo. J. Cell Sci. 2010, 123:1684-1692.
182. Cunha S.I., Pietras K. ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 2011, 117:6999-7006.
183. Shao E.S., Lin L., Yao Y., Bostrom K.I. Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood 2009, 114:2197-2206.
184. Park S.O., Lee Y.J., Seki T., Hong K.H., Fliess N., Jiang Z., Park A., Wu X., Kaartinen V., Roman B.L., Oh S.P. ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood 2008, 111:633-642.
185. He C., Chen X. Transcription regulation of the vegf gene by the BMP/Smad pathway in the angioblast of zebrafish embryos. Biochem. Biophys. Res. Commun. 2005, 329:324-330.
186. Larrivee B., Prahst C., Gordon E., del Toro R., Mathivet T., Duarte A., Simons M., Eichmann A. ALK1 signaling inhibits angiogenesis by cooperating with the Notch pathway. Dev. Cell 2012, 22:489-500.
187. Hu-Lowe D.D., Chen E., Zhang L., Watson K.D., Mancuso P., Lappin P., Wickman G., Chen J.H., Wang J., Jiang X., Amundson K., Simon R., Erbersdobler A., Bergqvist S., Feng Z., Swanson T.A., Simmons B.H., Lippincott J., Casperson G.F., Levin W.J., Stampino C.G., Shalinsky D.R., Ferrara K.W., Fiedler W., Bertolini F. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Cancer Res. 2011, 71:1362-1373.
188. van Meeteren L.A., Thorikay M., Bergqvist S., Pardali E., Stampino C.G., Hu-Lowe D., Goumans M.J., ten Dijke P. Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting. J. Biol. Chem. 2012, 287:18551-18561.
189. Dobaczewski M., Chen W., Frangogiannis N.G. Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J. Mol. Cell. Cardiol. 2011, 51:600-606.
190. Bujak M., Frangogiannis N.G. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc. Res. 2007, 74:184-195.
191. Bujak M., Ren G., Kweon H.J., Dobaczewski M., Reddy A., Taffet G., Wang X.F., Frangogiannis N.G. Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation 2007, 116:2127-2138.
192. Eddy A.A., Giachelli C.M. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int. 1995, 47:1546-1557.
193. Ikeuchi M., Tsutsui H., Shiomi T., Matsusaka H., Matsushima S., Wen J., Kubota T., Takeshita A. Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc. Res. 2004, 64:526-535.
194. Scharpfenecker M., Floot B., Korlaar R., Russell N.S., Stewart F.A. ALK1 heterozygosity delays development of late normal tissue damage in the irradiated mouse kidney. Radiother. Oncol. 2011, 99:349-355.
195. Chen Y., Kam C.S., Liu F.Q., Liu Y., Lui V.C., Lamb J.R., Tam P.K. LPS-induced up-regulation of TGF-beta receptor 1 is associated with TNF-alpha expression in human monocyte-derived macrophages. J. Leukoc. Biol. 2008, 83:1165-1173.
196. Scharpfenecker M., Floot B., Russell N.S., Stewart F.A. The TGF-beta co-receptor endoglin regulates macrophage infiltration and cytokine production in the irradiated mouse kidney. Radiother. Oncol. 2012, 105:313-320.
197. Rossi E., Sanz-Rodriguez F., Eleno N., Duwell A., Blanco F.J., Langa C., Botella L.M., Cabanas C., Lopez-Novoa J.M., Bernabeu C. Endothelial endoglin is involved in inflammation: role in leukocyte adhesion and transmigration. Blood 2013, 121:403-415.
198. Verrecchia F., Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J. Invest. Dermatol. 2002, 118:211-215.
199. Leask A., Abraham D.J., Finlay D.R., Holmes A., Pennington D., Shi-Wen X., Chen Y., Venstrom K., Dou X., Ponticos M., Black C., Bernabeu C., Jackman J.K., Findell P.R., Connolly M.K. Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum. 2002, 46:1857-1865.
200. Ruiz-Ortega M., Ruperez M., Esteban V., Egido J. Molecular mechanisms of angiotensin II-induced vascular injury. Curr. Hypertens. Rep. 2003, 5:73-79.
201. Li J.H., Huang X.R., Zhu H.J., Oldfield M., Cooper M., Truong L.D., Johnson R.J., Lan H.Y. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J. 2004, 18:176-178.
202. Rodriguez-Vita J., Sanchez-Lopez E., Esteban V., Ruperez M., Egido J., Ruiz-Ortega M. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 2005, 111:2509-2517.
203. Wang W., Huang X.R., Canlas E., Oka K., Truong L.D., Deng C., Bhowmick N.A., Ju W., Bottinger E.P., Lan H.Y. Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ. Res. 2006, 98:1032-1039.
204. Rodrigues Diez R., Rodrigues-Diez R., Lavoz C., Rayego-Mateos S., Civantos E., Rodriguez-Vita J., Mezzano S., Ortiz A., Egido J., Ruiz-Ortega M. Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-beta-independent process. PLoS One 2010, 5:e14145.
205. Pannu J., Asano Y., Nakerakanti S., Smith E., Jablonska S., Blaszczyk M., ten Dijke P., Trojanowska M. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum. 2008, 58:2528-2537.
206. Madri J.A., Reidy M.A., Kocher O., Bell L. Endothelial cell behavior after denudation injury is modulated by transforming growth factor-beta1 and fibronectin. Lab. Invest. 1989, 60:755-765.
207. Nikol S., Isner J.M., Pickering J.G., Kearney M., Leclerc G., Weir L. Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. J. Clin. Invest. 1992, 90:1582-1592.
208. Yutani C., Ishibashi-Ueda H., Suzuki T., Kojima A. Histologic evidence of foreign body granulation tissue and de novo lesions in patients with coronary stent restenosis. Cardiology 1999, 92:171-177.
209. Chamberlain J., Gunn J., Francis S.E., Holt C.M., Arnold N.D., Cumberland D.C., Ferguson M.W., Crossman D.C. TGFbeta is active, and correlates with activators of TGFbeta, following porcine coronary angioplasty. Cardiovasc. Res. 2001, 50:125-136.
210. Zeng W., Chen W., Leng X., He J.G., Ma H. Chronic angiotensin-(1-7) administration improves vascular remodeling after angioplasty through the regulation of the TGF-beta/Smad signaling pathway in rabbits. Biochem. Biophys. Res. Commun. 2009, 389:138-144.
211. Kundi R., Hollenbeck S.T., Yamanouchi D., Herman B.C., Edlin R., Ryer E.J., Wang C., Tsai S., Liu B., Kent K.C. Arterial gene transfer of the TGF-beta signalling protein Smad3 induces adaptive remodelling following angioplasty: a role for CTGF. Cardiovasc. Res. 2009, 84:326-335.
212. Tsai S., Butler J., Rafii S., Liu B., Kent K.C. The role of progenitor cells in the development of intimal hyperplasia. J. Vasc. Surg. 2009, 49:502-510.
213. Kobayashi K., Yokote K., Fujimoto M., Yamashita K., Sakamoto A., Kitahara M., Kawamura H., Maezawa Y., Asaumi S., Tokuhisa T., Mori S., Saito Y. Targeted disruption of TGF-beta-Smad3 signaling leads to enhanced neointimal hyperplasia with diminished matrix deposition in response to vascular injury. Circ. Res. 2005, 96:904-912.
214. Sluijter J.P., Verloop R.E., Pulskens W.P., Velema E., Grimbergen J.M., Quax P.H., Goumans M.J., Pasterkamp G., de Kleijn D.P. Involvement of furin-like proprotein convertases in the arterial response to injury. Cardiovasc. Res. 2005, 68:136-143.
215. Garrido-Martin E.M., Blanco F.J., Roque M., Novensa L., Tarocchi M., Lang U.E., Suzuki T., Friedman S.L., Botella L.M., Bernabeu C. Vascular injury triggers Kruppel-like factor 6 mobilization and cooperation with specificity protein 1 to promote endothelial activation through upregulation of the activin receptor-like kinase 1 gene. Circ. Res. 2013, 112:113-127.
216. Shovlin C.L., Guttmacher A.E., Buscarini E., Faughnan M.E., Hyland R.H., Westermann C.J., Kjeldsen A.D., Plauchu H. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am. J. Med. Genet. 2000, 91:66-67.
217. McAllister K.A., Lennon F., Bowles-Biesecker B., McKinnon W.C., Helmbold E.A., Markel D.S., Jackson C.E., Guttmacher A.E., Pericak-Vance M.A., Marchuk D.A. Genetic heterogeneity in hereditary haemorrhagic telangiectasia: possible correlation with clinical phenotype. J. Med. Genet. 1994, 31:927-932.
218. Gallione C.J., Repetto G.M., Legius E., Rustgi A.K., Schelley S.L., Tejpar S., Mitchell G., Drouin E., Westermann C.J., Marchuk D.A. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 2004, 363:852-859.
219. Bayrak-Toydemir P., McDonald J., Akarsu N., Toydemir R.M., Calderon F., Tuncali T., Tang W., Miller F., Mao R. A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am. J. Med. Genet. A 2006, 140:2155-2162.
220. Shovlin C.L. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev. 2010, 24:203-219.
221. Park S.O., Wankhede M., Lee Y.J., Choi E.J., Fliess N., Choe S.W., Oh S.H., Walter G., Raizada M.K., Sorg B.S., Oh S.P. Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J. Clin. Invest. 2009, 119:3487-3496.
222. Walker E.J., Su H., Shen F., Choi E.J., Oh S.P., Chen G., Lawton M.T., Kim H., Chen Y., Chen W., Young W.L. Arteriovenous malformation in the adult mouse brain resembling the human disease. Ann. Neurol. 2011, 69:954-962.
223. Corti P., Young S., Chen C.Y., Patrick M.J., Rochon E.R., Pekkan K., Roman B.L. Interaction between alk1 and blood flow in the development of arteriovenous malformations. Development 2011, 138:1573-1582.
224. Ricard N., Bidart M., Mallet C., Lesca G., Giraud S., Prudent R., Feige J.J., Bailly S. Functional analysis of the BMP9 response of ALK1 mutants from HHT2 patients: a diagnostic tool for novel ACVRL1 mutations. Blood 2010, 116:1604-1612.
225. Scotti C., Olivieri C., Boeri L., Canzonieri C., Ornati F., Buscarini E., Pagella F., Danesino C. Bioinformatic analysis of pathogenic missense mutations of activin receptor like kinase 1 ectodomain. PLoS One 2011, 6:e26431.
226. Fontalba A., Fernandez L.A., Garcia-Alegria E., Albinana V., Garrido-Martin E.M., Blanco F.J., Zarrabeitia R., Perez-Molino A., Bernabeu-Herrero M.E., Ojeda M.L., Fernandez-Luna J.L., Bernabeu C., Botella L.M. Mutation study of Spanish patients with hereditary hemorrhagic telangiectasia. BMC Med. Genet. 2008, 9:75.
227. Olivieri C., Pagella F., Semino L., Lanzarini L., Valacca C., Pilotto A., Corno S., Scappaticci S., Manfredi G., Buscarini E., Danesino C. Analysis of ENG and ACVRL1 genes in 137 HHT Italian families identifies 76 different mutations (24 novel). Comparison with other European studies. J. Hum. Genet. 2007, 52:820-829.
228. Abdalla S.A., Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J. Med. Genet. 2006, 43:97-110.
229. Fernandez L.A., Garrido-Martin E.M., Sanz-Rodriguez F., Pericacho M., Rodriguez-Barbero A., Eleno N., Lopez-Novoa J.M., Duwell A., Vega M.A., Bernabeu C., Botella L.M. Gene expression fingerprinting for human hereditary hemorrhagic telangiectasia. Hum. Mol. Genet. 2007, 16:1515-1533.
230. Humbert M., Deng Z., Simonneau G., Barst R.J., Sitbon O., Wolf M., Cuervo N., Moore K.J., Hodge S.E., Knowles J.A., Morse J.H. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur. Respir. J. 2002, 20:518-523.
231. Strange J.W., Wharton J., Phillips P.G., Wilkins M.R. Recent insights into the pathogenesis and therapeutics of pulmonary hypertension. Clin. Sci. (Lond.) 2002, 102:253-268.
232. Eyries M., Coulet F., Girerd B., Montani D., Humbert M., Lacombe P., Chinet T., Gouya L., Roume J., Axford M.M., Pearson C.E., Soubrier F. ACVRL1 germinal mosaic with two mutant alleles in hereditary hemorrhagic telangiectasia associated with pulmonary arterial hypertension. Clin. Genet. 2012, 82:173-179.
233. Girerd B., Montani D., Coulet F., Sztrymf B., Yaici A., Jais X., Tregouet D., Reis A., Drouin-Garraud V., Fraisse A., Sitbon O., O'Callaghan D.S., Simonneau G., Soubrier F., Humbert M. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am. J. Respir. Crit. Care Med. 2010, 181:851-861.
234. Shao D., Park J.E., Wort S.J. The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. Pharmacol. Res. 2011, 63:504-511.
235. Salani D., Taraboletti G., Rosano L., Di Castro V., Borsotti P., Giavazzi R., Bagnato A. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am. J. Pathol. 2000, 157:1703-1711.
236. Castanares C., Redondo-Horcajo M., Magan-Marchal N., ten Dijke P., Lamas S., Rodriguez-Pascual F. Signaling by ALK5 mediates TGF-beta-induced ET-1 expression in endothelial cells: a role for migration and proliferation. J. Cell Sci. 2007, 120:1256-1266.
237. Star G.P., Giovinazzo M., Langleben D. Bone morphogenic protein-9 stimulates endothelin-1 release from human pulmonary microvascular endothelial cells: a potential mechanism for elevated ET-1 levels in pulmonary arterial hypertension. Microvasc. Res. 2010, 80:349-354.
238. Park J.E., Shao D., Upton P.D., Desouza P., Adcock I.M., Davies R.J., Morrell N.W., Griffiths M.J., Wort S.J. BMP-9 induced endothelial cell tubule formation and inhibition of migration involves Smad1 driven endothelin-1 production. PLoS One 2012, 7:e30075.
239. Star G.P., Giovinazzo M., Langleben D. ALK2 and BMPR2 knockdown and endothelin-1 production by pulmonary microvascular endothelial cells. Microvasc. Res. 2013, 85:46-53.
240. Murshed M., Schinke T., McKee M.D., Karsenty G. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J. Cell Biol. 2004, 165:625-630.
241. Sinha S., Hoofnagle M.H., Kingston P.A., McCanna M.E., Owens G.K. Transforming growth factor-beta1 signaling contributes to development of smooth muscle cells from embryonic stem cells. Am. J. Physiol. Cell Physiol. 2004, 287:C1560-C1568.
242. Yao Y., Shao E.S., Jumabay M., Shahbazian A., Ji S., Bostrom K.I. High-density lipoproteins affect endothelial BMP-signaling by modulating expression of the activin-like kinase receptor 1 and 2. Arterioscler. Thromb. Vasc. Biol. 2008, 28:2266-2274.
243. Pawlikowska L., Tran M.N., Achrol A.S., Ha C., Burchard E., Choudhry S., Zaroff J., Lawton M.T., Castro R., McCulloch C.E., Marchuk D., Kwok P.Y., Young W.L. Polymorphisms in transforming growth factor-beta-related genes ALK1 and ENG are associated with sporadic brain arteriovenous malformations. Stroke 2005, 36:2278-2280.
244. Kim H., Marchuk D.A., Pawlikowska L., Chen Y., Su H., Yang G.Y., Young W.L. Genetic considerations relevant to intracranial hemorrhage and brain arteriovenous malformations. Acta Neurochir. Suppl. 2008, 105:199-206.
245. Sadick H., Riedel F., Naim R., Goessler U., Hormann K., Hafner M., Lux A. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 2005, 90:818-828.
246. Sadick H., Naim R., Gossler U., Hormann K., Riedel F. Angiogenesis in hereditary hemorrhagic telangiectasia: VEGF165 plasma concentration in correlation to the VEGF expression and microvessel density. Int. J. Mol. Med. 2005, 15:15-19.
247. Hao Q., Su H., Marchuk D.A., Rola R., Wang Y., Liu W., Young W.L., Yang G.Y. Increased tissue perfusion promotes capillary dysplasia in the ALK1-deficient mouse brain following VEGF stimulation. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H2250-H2256.
248. Yao Y., Jumabay M., Wang A., Bostrom K.I. Matrix Gla protein deficiency causes arteriovenous malformations in mice. J. Clin. Invest. 2011, 121:2993-3004.
249. Yan X., Lin Z., Chen F., Zhao X., Chen H., Ning Y., Chen Y.G. Human BAMBI cooperates with Smad7 to inhibit transforming growth factor-beta signaling. J. Biol. Chem. 2009, 284:30097-30104.